SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 12/8/2016 6:04:06 PM - Followers: 831 - Board type: Free - Posts Today: 53

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Amended Annual Report (10-k/a) 11/17/2016 04:05:38 PM
ELTP News: Amended Quarterly Report (10-q/a) 11/17/2016 04:03:30 PM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 11/09/2016 05:10:17 PM
ELTP News: Quarterly Report (10-q) 11/09/2016 04:42:48 PM
ELTP News: Current Report Filing (8-k) 09/01/2016 04:32:35 PM
PostSubject
#234974  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE namtae 12/01/16 09:52:20 AM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#233080  Sticky Note Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 Couch 11/11/16 04:34:51 AM
#222196  Sticky Note Freedom of Information Act Request to FDA WeeZuhl 08/17/16 07:21:46 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#235651   Nasrat has 3 solutions for final approval, which NASDAQ2020 12/08/16 06:04:06 PM
#235650   First bunch of NON-SENSE I heard, but won't stockboy 12/08/16 06:01:41 PM
#235649   The US bio pharmaceutical industry's two largest NASDAQ2020 12/08/16 05:57:36 PM
#235648   E L I T [color=purpl NASDAQ2020 12/08/16 05:52:24 PM
#235647   Only have to hit once! NASDAQ2020 12/08/16 05:49:49 PM
#235644   "Sure we will" - just like I was Couch 12/08/16 05:15:48 PM
#235643   Will be there again soon. Goodtimes93 12/08/16 05:13:53 PM
#235642   Are some still holding shares of this junk? Couch 12/08/16 05:12:47 PM
#235639   Are some still holding shares of this junk? You'll namtae 12/08/16 04:52:30 PM
#235637   While volume is low compared to the float, doncamel 12/08/16 03:26:34 PM
#235635   Thanks Snup. Always like your positivity. Lorie3168 12/08/16 02:40:36 PM
#235634   Jules, so true! regarding elite no worrys snupoled 12/08/16 02:32:29 PM
#235633   Some pounced on ELTP years ago, taking far julesnemo3 12/08/16 01:33:35 PM
#235632   What kind of reverse split are you thinking stockboy 12/08/16 01:32:50 PM
#235631   Richme, elite pharma, snupoled 12/08/16 01:19:04 PM
#235630   Hello Catty, snupoled 12/08/16 01:11:03 PM
#235629   ken, holding the fort till the whales pounce, snupoled 12/08/16 01:05:24 PM
#235628   Dr.Pete: I'm still in it - what about you? catty 12/08/16 01:00:58 PM
#235627   Folks still see value when ELTP traded in Aqua 12/08/16 12:59:56 PM
#235626   Hold on to the fort snup, The Elite kennyt 335 12/08/16 12:25:46 PM
#235625   Don't forget buy everything and anything @.35 and under. stockboy 12/08/16 12:24:32 PM
#235623   Meeees toooooos Nas!:-) kennyt 335 12/08/16 11:20:56 AM
#235620   Eyes Bee Buyin NASDAQ2020 12/08/16 10:54:49 AM
#235618   Not. Lol NASDAQ2020 12/08/16 10:47:39 AM
#235617   I will take solid green anyday but As jbdiver 12/08/16 10:21:05 AM
#235616   MR.wrn, all I can say is I personally am snupoled 12/08/16 09:52:39 AM
#235615   k mrwrn2010 12/08/16 09:49:40 AM
#235614   Elite in the $0.14's is just grand ............... IB_ 12/08/16 09:49:12 AM
#235613   Several decent sized orders on the bid this mrwrn2010 12/08/16 09:36:36 AM
#235609   Until we get a HEADS UP from the toybaby 12/08/16 08:11:49 AM
#235608   savvy investors are planning accordingly snupoled 12/08/16 08:02:50 AM
#235603   elite is not transport,defence or energy Dr_Thorfin 12/08/16 07:12:27 AM
#235602   Ow dow up 300 points nasdaq up 55 stockboy 12/08/16 07:01:46 AM
#235601   Quote- the market is soaring incase you haven't Dr_Thorfin 12/08/16 05:51:56 AM
#235600   The market is soaring incase you haven't noticed stockboy 12/08/16 04:23:58 AM
#235599   NFL close to replacing opioids with Marijuana Anti-inflammatory!!!! What namtae 12/08/16 03:15:44 AM
#235598   Well there isn't even 1 yet is there? stockboy 12/07/16 10:35:19 PM
#235597   Explanation Example: After there are 2 name brand ER ADF NASDAQ2020 12/07/16 10:29:48 PM
#235596   More NON-SENSE can you name 1 opiod that's stockboy 12/07/16 10:21:10 PM
#235595   The FDA will begin removing non-ADF opiods, leaving NASDAQ2020 12/07/16 10:14:04 PM
#235592   Elite poised to capture significant market share. NASDAQ2020 12/07/16 10:02:12 PM
#235591   Total nonsense but thanks dr_lowenstein 12/07/16 09:59:00 PM
#235585   Elite's unique, innovative , market disruptive 2 bead NASDAQ2020 12/07/16 09:47:35 PM
#235584   Elite's ADF opiods can not be abused by: NASDAQ2020 12/07/16 09:45:17 PM
#235580   Elite Pharma's unique, innovative, novel, market disruptive NDA NASDAQ2020 12/07/16 09:41:11 PM
#235578   I do it all the time, can't do stockboy 12/07/16 09:37:17 PM
#235577   TOTAL AND COMPLETE BS! stockboy 12/07/16 09:36:35 PM
#235576   NO HELP FOR GETTING ADT's PASSED no relation stockboy 12/07/16 09:35:25 PM
#235574   Great news helping ELTP NOT! Actually they are stockboy 12/07/16 09:23:22 PM
#235573   Thinking you can time the market and beat aELmTPa 12/07/16 09:22:11 PM
PostSubject